Drug intelligence / Profile preview

ABT-201

Development stage: Discontinued
Lead developer: Anbogen Therapeutics
Modality: Small Molecules

Overview

ABT-201 is a small molecule KRAS inhibitor that was under development by Anbogen Therapeutics for the treatment of non-small cell lung cancer (NSCLC). As part of the ABT-200 series, the compound was designed to target pan-KRAS gene mutations, aiming to inhibit the oncogenic signaling pathways driven by these mutations in cancers that lack approved targeted therapies. The program reached the hit-to-lead stage of preclinical development but has since been reported as discontinued by the developer.

Targets

KRAS (Kirsten rat sarcoma viral oncogene homolog)

Beyond the preview

Go deeper on ABT-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABT-201.

Explore the full profile